A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind and placebo-controlled trial with healthy subjects.
There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12
people. A single subcutaneous injection will be administrated starting from the low dose
group (in accordance with 5mg, 15mg, 30mg, 50mg, 75mg, 100mg administered subcutaneously).
Pharmacokinetics and pharmacodynamics data will be collected; drug metabolism and
pharmacokinetics characteristics will be analyzed. Drug safety and tolerance for subjects
will be evaluated.